Table 2. Tumor response to NAC in the two groups after PSM.

Variable	FLEEOX (n=99) (%)	XELOX (n=99) (%)	P
Response to NAC			0.026
CR	13 (13.1)	3 (3.0)
PR	67 (67.7)	65 (65.7)
SD	9 (9.1)	16 (16.2)
PD	10 (10.1)	15 (15.2)
RR (CR plus PR)	80 (80.8)	68 (68.7)	0.018
DCR (CR plus PR plus SD)	89 (89.9)	84 (84.8)	0.196

PSM, propensity score matching; FLEEOX, 5-Fu, leucovorin, etoposide, epirubicin and oxaliplatin; XELOX, capecitabine and oxaliplatin; CR, complete response; PR, partial response; SD, stable disease; PD, progression disease; RR, response rate; DCR, disease control rate